HAVN Life Sciences Inc. (HAVLF)
HAVN Life Sciences Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Port Moody, BC, CA. The stock last traded at $0.00, up 0.00% on the session, giving a market capitalisation of $2,565. On trailing twelve-month figures it carries a trailing P/E of -0.01, a net margin of -8117.8%. Its beta of -0.30 implies it has historically moved less than the broad market.
HAVN Life Sciences Inc. is a biotechnology firm dedicated to the research and creation of psychotropic compounds sourced from flora and fungi. The company's expertise includes devising standardized and quality-assured extraction techniques for psychoactive substances, particularly from Psilocybe mushrooms, to isolate key compounds such as psilocybin, psilocin, and baeocystin. Furthermore, it develops natural health remedies using non-regulated ingredients. This Canadian company, founded in 2020, is headquartered in Richmond.
HAVN Life Sciences Inc. is most often compared with the following Healthcare names: